Lineage Cell Therapeutics, Inc. Stock News

Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET Company Participants Ioana Hone - Head of IR Brian Culley - CEO Jill Howe - CFO Conference Call P

By corporate protocol and just plain old common sense, when it comes to penny stocks to buy, your first instinct should be this: don't. Yeah, I know that's not exactly a sexy opener for the topic at h

Start Time: 16:30 January 1, 0000 5:12 PM ET Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q3 2023 Earnings Conference Call November 09, 2023, 16:30 PM ET Company Participants Brian Culley - CEO Jill H

Longevity stocks have started to come on many investors' radars. These companies come with the promise of stable returns over the long run as human life continues to stretch further ahead.

Lineage Cell Therapeutics is a clinical-stage biotechnology company focused on developing cell therapies for degenerative diseases. The shares trade for just over a buck apiece. Five analyst firms hav

Lineage Cell (LCTX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.04 per share a year ago.

Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q1 2023 Results Conference Call May 11, 2023 4:30 PM ET Company Participants Ioana Hone - Head of Investor Relations Brian Culley - Chief Executive Officer

Penny stocks to buy have been the talk of the town in recent weeks as cyclical assets have started to make a comeback this year. Penny stocks tend to perform poorly during market downturns.

Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q4 2022 Earnings Conference Call March 9, 2023 4:30 PM ET Company Participants Ioana Hone - Head of IR Brian Culley - CEO Jill Howe - Chief Financial Offic

Lineage Cell (LCTX) delivered earnings and revenue surprises of 0% and 35.46%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

CARLSBAD, Calif.--( BUSINESS WIRE )--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs

Lineage Cell (LCTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Ioana Hone - Head of IR Brian Culley - CEO and Interim CFO Gary Hogge -

Lineage Cell (LCTX) delivered earnings and revenue surprises of -33.33% and 26.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Anti-aging stocks have not proven immune to poor market conditions that have plagued the broader biotech industry. The biotech industry remains hampered by the same bleak economic conditions as those